Aiswarya U S

Employment

• Centre of Excellence in Nutraceuticals Research Associate
  2025 - Present
• CSIR-NIIST Chief Minister's Nava Kerala Post Doctoral Fellow (CMNPF)
  2023 - Present
• Rajiv Gandhi Centre for Biotechnology Project Fellow, Spices Board of India
  2022 - Present
• Rajiv Gandhi Centre for Biotechnology SRF, ICMR
  2022 - 2023

Education

• University of Calicut Ph.D
  2016 - 2022
• Narayana Dental College and Hospital MSc
  2013 - 2015
• Govt. Arts College BSc
  2010 - 2013

Projects & Funding

Projects & funding information is unavailable.

Publications (11)

• Designing JAK2 Inhibitors Beyond Myeloproliferative Neoplasms ‐ Theoretical and Experimental Analysis for Solid Cancers
  A. S. Achutha, S. Krishna, V.L. Pushpa

  +11 more

  • Deivendran Harshini
  • Sreekumar Usha Devi Aiswarya
  • Samuthira Nagarajan
  • Ruby John Anto
  • Vinod Balachandran
  • +6 more
  ChemistrySelect 2024 DOI: 10.1002/slct.202400072
  +Save
• A novel combinatorial regimen using sorafenib and uttroside B, a US FDA-approved phytosaponin, for the treatment of hepatocellular carcinoma
  Anti-cancer agents in Medicinal Chemistry 2024
  +Save
• Evaluation of Uttroside B, a potent bioactive from Solanum nigrum Linn, as a candidate drug molecule against Non-Alcoholic Fatty Liver Disease
  Biomedicine 2024
  +Save
• Putative role of uttronin (degalactotigonin) in cytotoxicity of uttroside B in HepG2 cells
  Sanjay Suresh Varma, Sreekumar Usha Devi Aiswarya, Chenicheri Kizhakkeveettil Keerthana +4 more
  Tetrahedron Letters 2023 DOI: 10.1016/j.tetlet.2023.154668
  +Save
• Targeting receptor tyrosine kinase signaling: Avenues in the management of cutaneous squamous cell carcinoma
  iScience 2023
  +Save
• A potent bioactive fraction against colon cancer from Plectranthus vettiveroides
  Faisal Moossa Athikkavil, Sreekumar Usha Devi Aiswarya, Remya Johny +5 more
  Exploration of Targeted Anti-tumor Therapy 2023 DOI: 10.37349/etat.2023.00131
  +Save
• Pharmacological attenuation of melanoma by tryptanthrin pertains to the suppression of MITF-M through MEK/ERK signaling axis
  Anwar Shabna, Jayesh Antony, Vinod Vijayakurup

  +16 more

  • Minakshi Saikia
  • Vijayasteltar Belsamma Liju
  • Archana Payickattu Retnakumari
  • Amrutha Nisthul A.
  • Vijai V. Alex
  • +11 more
  Cellular and Molecular Life Sciences 2022 DOI: 10.1007/s00018-022-04476-y
  +Save
• Cucurbitacin B, Purified and Characterized From the Rhizome of Corallocarpus epigaeus Exhibits Anti-Melanoma Potential
  Sreekumar Usha Devi Aiswarya, Gowda Vikas, Nair Hariprasad Haritha +12 more
  Frontiers in Oncology 2022 DOI: 10.3389/fonc.2022.903832
  +Save
• Augmented Efficacy of Uttroside B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma
  Mundanattu Swetha, Chenicheri Kizhakkeveettil Keerthana, Tennyson Prakash Rayginia +17 more
  Pharmaceuticals 2022 DOI: 10.3390/ph15050636
  +Save
• Blockade of Uttroside B-Induced Autophagic Pro-Survival Signals Augments Its Chemotherapeutic Efficacy Against Hepatocellular Carcinoma
  Lekshmi R. Nath, Mundanattu Swetha, Vinod Vijayakurup +13 more
  Frontiers in Oncology 2022 DOI: 10.3389/fonc.2022.812598
  +Save
• Targeting Thymidylate Synthase Enhances the Chemosensitivity of Triple-Negative Breast Cancer Towards 5-FU-Based Combinatorial Therapy
  Nair Hariprasad Haritha, Akbar Nawab, Vinod Vijayakurup

  +16 more

  • Nikhil Ponnoor Anto
  • Vijayasteltar Belsamma Liju
  • Vijai V. Alex
  • Areekkara Nisthul Amrutha
  • Sreekumar Usha Devi Aiswarya
  • +11 more
  Frontiers in Oncology 2021 DOI: 10.3389/fonc.2021.656804
  +Save